WAGISTRASSE 14, Z?RICH-SCHLIEREN, V8
Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
Material disclosure
Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
Condensed Consolidated Interim Financial Statements
Publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
Announces All Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Amended Schedule 13D - Ownership Report
Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Correspondence
Submission Upload
SEC Staff Correspondence
Free Writing Prospectus